A5025535129- Antifungal resistance and susceptibility
- Fungal Infections and Studies
- Neutropenia and Cancer Infections
- Transplantation: Methods and Outcomes
- Pneumocystis jirovecii pneumonia detection and treatment
- Bacterial Identification and Susceptibility Testing
- Pneumonia and Respiratory Infections
- Antibiotics Pharmacokinetics and Efficacy
- Infectious Diseases and Mycology
- Mycobacterium research and diagnosis
- Antimicrobial Resistance in Staphylococcus
- Polyomavirus and related diseases
- Pericarditis and Cardiac Tamponade
- Pleural and Pulmonary Diseases
- Antibiotic Resistance in Bacteria
- Nosocomial Infections in ICU
- Respiratory viral infections research
- Cytomegalovirus and herpesvirus research
- Pulmonary Hypertension Research and Treatments
- Trauma Management and Diagnosis
- Nail Diseases and Treatments
- Plant Pathogens and Fungal Diseases
- Infectious Diseases and Tuberculosis
- Surgical site infection prevention
- Renal Transplantation Outcomes and Treatments
University of Toronto
2015-2025
University Health Network
2016-2025
Ted Rogers Centre for Heart Research
2024
Toronto General Hospital
2008-2023
Health Net
2020
Biology of Infection
2018
Engineering Associates (United States)
2017-2018
Office of Infectious Diseases
2003-2017
Toronto Public Health
2016
University Medical Center Groningen
2013
Caspofungin is an echinocandin agent with fungicidal activity against candida species. We performed a double-blind trial to compare caspofungin amphotericin B deoxycholate for the primary treatment of invasive candidiasis.We enrolled patients who had clinical evidence infection and positive culture species from blood or another site. Patients were stratified according severity disease, as indicated by Acute Physiology Chronic Health Evaluation (APACHE II) score, presence absence neutropenia...
Anidulafungin, a new echinocandin, has potent activity against candida species. We compared anidulafungin with fluconazole in randomized, double-blind, noninferiority trial of treatment for invasive candidiasis.
This analysis describes the epidemiology and outcomes of invasive candidiasis caused by non-albicans species Candida in patients enrolled Prospective Antifungal Therapy Alliance (PATH Alliance) registry from 2004 to 2008. A total 2,496 with isolates were identified. The identified C. glabrata (46.4%), parapsilosis (24.7%), tropicalis (13.9%), krusei (5.5%), lusitaniae (1.6%), dubliniensis (1.5%) guilliermondii (0.4%); 111 infections involved two or more (4.4%). Non-albicans accounted for...
Invasive fungal infections are of importance and increasing in incidence immunocompromised hosts such as patients who have had hematopoietic stem cell solid organ transplants. Despite our expanded antifungal armamentarium, these cause considerable morbidity mortality. Indeed, certain trends emerged invasive infections: a rise the mold infections, an increase non-albicans strains Candida spp. causing disease and, finally, emergence less susceptible that resistant to broader-spectrum agents...
Hospital-acquired pneumonia (HAP) and ventilator-associated (VAP) are important causes of morbidity mortality, with mortality rates approaching 62%. HAP VAP the second most common cause nosocomial infection overall, but documented in intensive care unit setting. In addition, produce highest associated infection. As a result, evidence-based guidelines were prepared detailing epidemiology, microbial etiology, risk factors clinical manifestations VAP. Furthermore, an approach based on available...
A randomized, double-blind trial comparing oral fluconazole (400 mg daily) with placebo as prophylaxis for adult patients receiving intensive cytotoxic therapy acute leukemia or autologous bone marrow transplantation was conducted in 14 Canadian university-affiliated hospitals. Although did not obviate the need parenteral antifungal compared (81 [57%] of 141 vs. 67 [50%] 133, respectively), its use resulted fewer superficial fungal infections (10 [7%] 23 [18%] 131, respectively; P = .02) and...
The annual standard-dose (SD) influenza vaccine has suboptimal immunogenicity in solid organ transplant recipients (SOTRs). Influenza that contains higher doses of antigens may lead to greater this population.We conducted a randomized, double-blind trial compare the safety and 2016-2017 high-dose (HD; FluzoneHD, Sanofi) vs SD (Fluviral, GSK) adult SOTRs. Preimmunization 4-week postimmunization sera underwent strain-specific hemagglutination inhibition assay.We enrolled 172 patients who...
Isavuconazole was compared to caspofungin followed by oral voriconazole in a Phase 3, randomized, double-blind, multinational clinical trial for the primary treatment of patients with candidemia or invasive candidiasis.Adult were randomized 1:1 isavuconazole (200 mg intravenous [IV] three-times-daily [TID] 2 days, 200 IV once-daily [OD]) (70 OD on day 1, 50 [70 > 80 kg]) maximum 56 days. After 10, could switch (isavuconazole arm) (caspofungin arm). Primary efficacy endpoint successful...
Abstract These updated guidelines from the American Society of Transplantation Infectious Diseases Community Practice provide recommendations for diagnosis and management Candida infections in solid organ transplant recipients. manifest primarily as candidemia invasive candidiasis cause considerable morbidity mortality. Early initiation treatment are necessary to reduce For both candidiasis, an echinocandin is recommended initial therapy. However, early transition oral therapy encouraged...
Background. The empirical treatment of febrile, neutropenic patients with cancer requires antibacterial regimens active against both gram-positive and gram-negative pathogens. This study was performed to demonstrate the noninferiority monotherapy piperacillin-tazobactam, compared cefepime.
Background Invasive aspergillosis (IA) is an important cause of morbidity and mortality among patients undergoing lung transplant. Cystic fibrosis-lung transplant recipients (CF-LTRs) may be at greater risk IA following transplantation because the presence Aspergillus in their airways before transplantation. This study evaluated impact pretransplant colonization on for CF-LTRs. Methods A single-center retrospective cohort CF-LTRs was conducted between 2006 2010. Respiratory tract cultures...
Candida albicans is the most common cause of candidemia and other forms invasive candidiasis. Systemic infections due to C. exhibit good susceptibility fluconazole echinocandins. However, echinocandin anidulafungin was recently demonstrated be more effective than for systemic in a randomized, double-blind trial among 245 patients. In that trial, were caused by albicans, all respective isolates susceptible randomized study drug. We sought better understand factors associated with enhanced...
Renal transplant recipients are at increased risk for developing invasive pneumococcal disease but may have a poor response to polysaccharide vaccine (PPV23). For them, conjugate (PCV7) be more immunogenic. Patients were given single dose of PPV23 or PCV7 in our randomized, controlled, double-blind trial. Immunogenicity was assessed 8 weeks after vaccination by serotype-specific enzyme-linked immunosorbent assay (ELISA) and opsonophagocytic (OPA). Baseline demographics, renal function, time...
Abstract Between April 1982 and March 1983,10 of 26 (38.4%) allogeneic bone marrow transplant recipients housed on a newly opened unit developed invasive aspergillosis. By contrast, between September 1977 1982, only 3 46 (6%) A case-control study to identify host factors related Aspergillus infection found that aspergillosis was more common in patients with chronic myelogenous leukemia aplastic anemia, older patients, having cytomegalovirus disease, who experienced prolonged...